10th Oct 2018 11:49
LONDON (Alliance News) - Silence Therapeutics PLC said Wednesday it filed a cross-border interim injunction application to stop Alnylam Pharmaceuticals Inc from commercialising patisiran drug across Europe.
Patisiran drug uses human body's natural mechanism of RNA interference within its cells to curtail the production of disease-associated proteins.
The company filed the injunction in the Netherlands, where Alnylam holds its marketing authorisation for Onpattro, its version of patisiran, requesting the courts to prohibit Alnylam from commercialising it.
Silence had been in dispute with Alnylam, saying its patisiran is an infringement on its intellectual property. A UK trial is set to begin in December with a decision early 2019.
Silence Therapeutics said: "Despite requests not to do so, Alnylam has openly commercialised Onpattro in the face of the Silence claims."
"The company therefore feels that it has been left with no alternative other than to take the necessary steps to enforce its patents and protect the historic investment made in its technology."
Shares in Silence Therapeutics were flat at 121.00 pence each.
Related Shares:
SLN.L